COL5A2 was reported to be correlated with poor clinical outcomes of bladder cancer patients, suggesting that it could serve as a cancer biomarker (Zeng, Liu, Liu, & Wang, 2018). Here, COL5A2 is linked to urinary bladder carcinoma.